Healthcare | October 11, 2021
HealthEdge opens its facility in Pune
The Pune centre expands its presence beyond Bangalore and Hyderabad
The Pune centre expands its presence beyond Bangalore and Hyderabad
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
It recommends using the vaccine to prevent the spread of the disease
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
The transaction is anticipated to close in the first quarter of 2022
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
Its store network grew from 144 stores in March 2019 to 236 stores. It has a presence in 23 cities across Maharashtra, Goa and Karnataka, employing more than 4,600 people.
A total of 707 district hospitals across all states and union territories participated in the performance assessment. The Health Management Information System (HMIS) data for the year 2017–18 has been used as a baseline for this exercise
Subscribe To Our Newsletter & Stay Updated
